Migraine and asthma are two of the most common chronic conditions affecting the nervous and respiratory systems respectively, and they co-occur at rates that substantially exceed what chance would predict. People with asthma are approximately twice as likely to have migraine compared to people without asthma, and the association holds across multiple study populations, age groups, and geographic settings. The relationship reflects shared underlying biology rather than coincidence or the stress of managing one chronic condition causing another.
Understanding what migraine and asthma have in common at the biological level, how each condition may influence the other, and what management considerations arise from their co-occurrence helps people with both conditions and their healthcare providers take a more integrated approach to care.
Both migraine and asthma are associated with atopic constitution, a heightened immunological reactivity to environmental stimuli. Mast cells, which are central players in both allergic asthma and migraine neuroinflammation, are activated in both conditions and release overlapping mediators including histamine, prostaglandins, and leukotrienes. The mast cell connection provides a direct immunological bridge between conditions that on the surface appear to involve different organ systems.
Systemic inflammation provides another shared mechanism. Pro-inflammatory cytokines including interleukin-4, interleukin-5, and interleukin-13 that drive allergic airway inflammation in asthma have also been detected in elevated levels in migraine patients. Chronic low-grade systemic inflammation may lower the threshold for both asthma exacerbations and migraine attacks through its effects on mast cell sensitivity and pain system excitability.
Autonomic nervous system dysregulation is a feature of both migraine and asthma. In migraine, autonomic symptoms including nasal congestion, facial flushing, and sweating during attacks reflect hypothalamic and brainstem autonomic involvement. In asthma, parasympathetic dominance contributes to bronchoconstriction through the cholinergic pathway.
The overlap in autonomic dysregulation between the two conditions may explain some of their clinical co-occurrence and provides a mechanistic framework for understanding why both conditions tend to be more reactive to the same classes of environmental triggers including allergens, exercise, emotional stress, and weather changes.
Asthma-related hypoxia during exacerbations can lower the migraine threshold through mechanisms similar to those involved in sleep apnea and altitude exposure. Even mild reductions in oxygen saturation promote cerebral vasodilation and may activate trigeminal pain pathways.
Medications used for asthma management have variable effects on migraine. Beta-2 agonist bronchodilators including albuterol cause peripheral and potentially central vasodilation that may trigger or worsen migraine in some people. Inhaled corticosteroids, which are the cornerstone of asthma controller therapy, do not have direct effects on migraine but their systemic anti-inflammatory effects may have indirect benefits.
Several beta-blocker medications used for migraine prevention, including propranolol and metoprolol, are contraindicated or require caution in people with asthma because beta-blockade can cause bronchoconstriction in susceptible individuals. This pharmacological contraindication means that the standard migraine prevention approach must be modified for people with both conditions, favoring alternatives including valproate, topiramate, amitriptyline, or CGRP monoclonal antibodies that do not affect beta-adrenergic receptors.
Discussing both conditions comprehensively with a healthcare provider who is aware of both the migraine and asthma diagnoses ensures that treatment choices for one condition do not inadvertently worsen the other.
Because migraine and asthma share many of the same environmental triggers including allergens, exercise, emotional stress, and air pollution, trigger management strategies that benefit one condition often benefit both. Allergen avoidance measures, air quality monitoring, consistent exercise with appropriate warm-up and hydration, and stress management techniques that reduce autonomic reactivity are worth pursuing as part of a comprehensive approach to managing both conditions simultaneously.
Davey G, Sedgwick P, Maier W, et al. Association between migraine and asthma: matched case-control study. British Journal of General Practice. 2002.
Brandes JL. Global trends in migraine care: results from the MAZE survey. CNS Drugs. 2002.
Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. Journal of Neuroscience. 2015.
American Migraine Foundation. Migraine and Co-occurring Conditions. americanmigrainefoundation.org
Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiological Reviews. 2017.
Co-occurrence rates in veteran and civilian populations, shared HPA axis and amygdala mechanisms, allodynia overlap, how PTSD sleep disruption worsens migraine, and integrated treatment options.
What central sensitization is, how it manifests in both conditions, reduced descending pain inhibition, clinical implications of co-occurrence, and treatment overlap.
Co-occurrence rates, the enteric nervous system and serotonin, mast cells as a connecting mechanism, shared nausea pathways, and treatments that address both conditions.
Prevalence of tinnitus in migraine, auditory cortex hyperexcitability, the trigeminal-auditory connection, vestibular migraine and auditory symptoms, and coordinated management.
Tracking your migraines changes everything. MigraClarity helps you log attacks, identify triggers, monitor medications, and track sleep and hydration — then generates a provider-ready report you can bring to your next appointment. Create your free account and start building a clearer picture of your migraine pattern today.
Create Your Free AccountThe information in this article is intended for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional or licensed physician before making any decisions about your health, medications, or treatment. MigraClarity is not a medical provider and nothing on this site should be used as a substitute for professional medical care.